New drug duo aims to outsmart Hard-to-Treat lymphoma
NCT ID NCT06948786
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether combining two drugs, pirtobrutinib and mosunetuzumab, can better treat follicular lymphoma that has relapsed or is refractory. Pirtobrutinib blocks a protein that helps cancer cells grow, while mosunetuzumab helps the body's immune T cells attack the cancer. The study will enroll 22 adults with grade 1-3a follicular lymphoma who have already tried at least two prior treatments. Researchers hope this combo improves remission rates and reduces side effects like cytokine release syndrome.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pirtobrutinib and mosunetuzumab
- What this could lead to
- If successful, this combination could offer a more effective treatment option for patients with follicular lymphoma that has returned or not responded to prior therapies, potentially with fewer severe side effects.
- What could go wrong
- This is a small, early-phase trial with only 22 participants, so results may not apply broadly. The combination may not work as hoped, and side effects like cytokine release syndrome remain a risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRADE 1 FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can two immune boosters outsmart follicular lymphoma without chemo?
- Triple-Drug cocktail aims to boost remission in follicular lymphoma
- Targeted drug combo aims to tackle Hard-to-Treat lymphoma
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- New drug combo shows early promise for recurrent lymphoma
- Gene therapy takes on HIV and cancer in one shot